Urgency For Approval Of OTC Naloxone In US Weighed Against Using Untested Package Labeling

 
• By Malcolm Spicer
  
The joint advisory committee voted unanimously that the benefit-risk calculation supported nonprescription use. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers